The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy

2017 ◽  
Vol 67 (3) ◽  
pp. 381-392 ◽  
Author(s):  
David Briere ◽  
Niranjan Sudhakar ◽  
David M. Woods ◽  
Jill Hallin ◽  
Lars D. Engstrom ◽  
...  
Keyword(s):  
Antigen Presentation ◽  
Tumor Antigen ◽  
Hdac Inhibitor ◽  
Checkpoint Inhibitor ◽  
Cell Types ◽  
Inhibitor Therapy ◽  
Class I ◽  
Checkpoint Inhibitor Therapy

A Systematic Review of Cases of Diabetes Mellitus following Immune Checkpoint Inhibitor Therapy for Cancer

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 204-LB ◽  
Author(s):  
KARA R. MIZOKAMI-STOUT ◽  
ROMA GIANCHANDANI ◽  
MARK MACEACHERN ◽  
RAVI M. IYENGAR ◽  
SARAH YENTZ ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Systematic Review ◽  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Inhibitor Therapy ◽  
Checkpoint Inhibitor Therapy

scholarly journals Collaboration Between Rheumatology and Oncology in Immune Checkpoint Inhibitor Therapy

2018 ◽  
Vol 36 (26) ◽  
pp. 2743-2744 ◽  
Author(s):  
Donald L. Kimpel ◽  
Janet E. Lewis ◽  
Elizabeth Gaughan ◽  
William W. Grosh ◽  
Christiana Brenin
Keyword(s):  
Immune Checkpoint ◽  
Immune Checkpoint Inhibitor ◽  
Checkpoint Inhibitor ◽  
Inhibitor Therapy ◽  
Checkpoint Inhibitor Therapy
Sign in / Sign up

Export Citation Format

Share Document